Acute On Chronic Liver Failure (ACLF) Pipeline Insight

DelveInsight’s, “Acute on Chronic Liver Failure Pipeline Insight 2026” report provides comprehensive insights about 3+ companies and 5+ pipeline drugs in Acute on Chronic Liver Failure (ACLF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute on Chronic Liver Failure Understanding

Acute on Chronic Liver Failure Overview

Acute-on-chronic liver failure (ACLF) is a clinical syndrome characterized by sudden hepatic decompensation observed in patients with preexisting chronic liver disease (CLD). This condition is associated with 1 or more extrahepatic organ failures and increased risk of mortality. The initial classification of ACLF divided the condition into 3 types. Type-A ACLF refers to the acute worsening of liver function in a patient with chronic liver disease. Type-B ACLF describes acute decompensation in patients with cirrhosis, while type-C ACLF involves acute deterioration of patients with previously decompensated cirrhosis. The symptoms usually involve acute deterioration of liver function manifesting as liver failure and other non-hepatic organ failures with high short-term mortality.

The pathophysiology of ACLF is based on the understanding that an acute precipitating event in a patient with a chronic liver condition causes hepatocellular injury, triggering a cascade of inflammatory cytokines and resulting in further hepatic injury, particularly impaired hepatocyte regeneration. The resulting immune dysfunction and hepatic decompensation increase the patient's vulnerability to infections, ultimately contributing to multiple organ failure and high mortality.
Systemic inflammation, characterized by elevated leukocytosis, cytokines, and chemokines (including interleukin-6 and interleukin-8), is commonly observed in patients with ACLF. This inflammatory response is typically absent in patients with compensated cirrhosis without ACLF. Bacteria-induced pathogen-associated molecular patterns (PAMPS) and virulence factors activate transcription factors that drive cytokine expression in the inflammatory cascade. In addition, endogenous inducers of inflammation, known as damage-associated molecular patterns (DAMPs) released from injured or necrotic hepatocytes also activate inflammatory pathways. These DAMPs interact with Toll-like receptors (TLRs) to amplify the immune response. This immunopathology plays a role in causing tissue and organ damage, ultimately leading to multiple organ failure in patients with ACLF. 

The etiology of ACLF typically involves a precipitating event occurring in the setting of a preexisting liver condition. Hepatic triggers include alcohol-associated hepatitis, drug-induced liver injury, viral hepatitis (A, B, C, D, and E), hypoxic injury, or liver-related procedures, including transjugular intrahepatic portosystemic shunt placement. Extrahepatic causes are primarily bacterial infections and major surgical interventions. Notably, in approximately 40% to 50% of cases, no identifiable precipitating event is found, and these patients are categorized as having an unrecognized trigger for ACLF.

Patients with ACLF typically present with features of acute hepatic decompensation. Common laboratory abnormalities include a prolonged international normalized ratio of 1.5 or greater, elevated bilirubin and aminotransferases, thrombocytopenia with anemia, hypoglycemia, elevated ammonia levels, and evidence of acute kidney injury (AKI), often reflected by increased serum creatinine and electrolyte imbalances. Managing ACLF involves preventing precipitating factors that lead to acute hepatic decompensation, providing supportive care, and initiating specific therapies early. Management also includes preventing and managing complications, assessment of prognosis, and evaluation for liver support, including possible need for liver transplantation. All patients should be hospitalized, preferably at a center with the necessary facilities and expertise for liver transplantation.

"Acute on Chronic Liver Failure Pipeline Insight 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute on Chronic Liver Failure (ACLF) pipeline landscape is provided which includes the disease overview and Acute on Chronic Liver Failure (ACLF) treatment guidelines. The assessment part of the report embraces, in depth Acute on Chronic Liver Failure (ACLF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute on Chronic Liver Failure (ACLF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Acute on Chronic Liver Failure pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Acute on Chronic Liver Failure Pipeline Report Highlights

The Acute on Chronic Liver Failure companies and academics are working to assess challenges and seek opportunities that could influence Acute on Chronic Liver Failure (ACLF) R&D. The therapies under development are focused on novel approaches to treat/improve Acute on Chronic Liver Failure (ACLF).

Acute on Chronic Liver Failure (ACLF) Emerging Drugs Chapters

This Acute on Chronic Liver Failure segment of the Acute on Chronic Liver Failure (ACLF) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute on Chronic Liver Failure Emerging Drugs

G1090N: Genfit

G1090N is an investigational gene therapy candidate being explored for acute-on-chronic liver failure (ACLF), designed to modulate key molecular pathways involved in hepatic inflammation, injury, and regeneration. It is believed to utilize a viral vector platform (such as adeno-associated virus or similar delivery systems) to enable targeted hepatic delivery and sustained expression of therapeutic transgenes. Mechanistically, G1090N aims to attenuate systemic and intrahepatic inflammation, reduce hepatocellular apoptosis and necrosis, and enhance regenerative signaling pathways within the liver microenvironment. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Acute on Chronic Liver Failure (ACLF).

Further product details are provided in the report……..

Acute on Chronic Liver Failure Drug Therapeutic Assessment

This Acute on Chronic Liver Failure segment of the report provides insights about the different Acute on Chronic Liver Failure (ACLF) drugs segregated based on following parameters that define the scope of the report, such as:

Major Acute on Chronic Liver Failure Players in Acute on Chronic Liver Failure

There are approx. 3+ key companies which are developing the therapies for Acute on Chronic Liver Failure (ACLF). The companies which have their Acute on Chronic Liver Failure (ACLF) drug candidates in the most advanced stage, i.e. phase I include, Genfit.

Acute on Chronic Liver Failure Clinical Trial Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Acute on Chronic Liver Failure Drug Route of Administration

Acute on Chronic Liver Failure (ACLF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Acute on Chronic Liver Failure Product Molecule Type

Acute on Chronic Liver Failure Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Acute on Chronic Liver Failure Product Type

Acute on Chronic Liver Failure Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute on Chronic Liver Failure Clinical Trial Activities

The Acute on Chronic Liver Failure pipeline report provides insights into  Acute on Chronic Liver Failure Clinial trials in phase II, I, preclinical and discovery stage. It also analyses Acute on Chronic Liver Failure (ACLF) therapeutic drugs key players involved in developing key drugs.

Acute on Chronic Liver Failure Pipeline Development Activities

The Acute on Chronic Liver Failure Clinial trials analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute on Chronic Liver Failure (ACLF) drugs.

Acute on Chronic Liver Failure (ACLF) Report Insights

• Acute on Chronic Liver Failure (ACLF) Pipeline Analysis
• Acute on Chronic Liver Failure Therapeutic Assessment
• Acute on Chronic Liver Failure Maket Unmet Needs
• Impact of Acute on Chronic Liver Failure Drugs

Acute on Chronic Liver Failure (ACLF) Report Assessment

• Acute on Chronic Liver Failure Pipeline Product Profiles
• Therapeutic Acute on Chronic Liver Failure Assessment
• Acute on Chronic Liver Failure Pipeline Assessment
• Inactive Acute on Chronic Liver Failure drugs assessment
• Acute on Chronic Liver Failure Unmet Needs

Discover actionable insights into the Acute on Chronic Liver Failure market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Acute on Chronic Liver Failure Pipeline Report

Current Treatment Scenario and Emerging Therapies:

• How many Acute on Chronic Liver Failure companies are developing Acute on Chronic Liver Failure (ACLF) drugs?
• How many Acute on Chronic Liver Failure (ACLF) drugs are developed by each company?
• How many Acute on Chronic Liver Failure emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute on Chronic Liver Failure (ACLF)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute on Chronic Liver Failure (ACLF) therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Acute on Chronic Liver Failure (ACLF) and their status?
• What are the key designations that have been granted to the emerging drugs?

Acute on Chronic Liver Failure Key Companies

• Genfit
• Gyre Therapeutics

Acute on Chronic Liver Failure Key Products

• G1090N
• F573"

Explore comprehensive insights into Acute on Chronic Liver Failure epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.